232 related articles for article (PubMed ID: 34833913)
21. Pharmacophoric characteristics of dengue virus NS2B/NS3pro inhibitors: a systematic review of the most promising compounds.
Leonel CA; Lima WG; Dos Santos M; Ferraz AC; Taranto AG; de Magalhães JC; Dos Santos LL; Ferreira JMS
Arch Virol; 2018 Mar; 163(3):575-586. PubMed ID: 29147793
[TBL] [Abstract][Full Text] [Related]
22. [1,2,4]Triazolo[1,5-a]pyrimidine derivative (Mol-5) is a new NS5-RdRp inhibitor of DENV2 proliferation and DENV2-induced inflammation.
Wan YH; Wu WY; Guo SX; He SJ; Tang XD; Wu XY; Nandakumar KS; Zou M; Li L; Chen XG; Liu SW; Yao XG
Acta Pharmacol Sin; 2020 May; 41(5):706-718. PubMed ID: 31729469
[TBL] [Abstract][Full Text] [Related]
23.
Banjan B; Krishnan D; Koshy AJ; Soman S; Leelamma A; Raju R; Revikumar A
J Biomol Struct Dyn; 2024 Jul; 42(11):5963-5981. PubMed ID: 37394810
[TBL] [Abstract][Full Text] [Related]
24. Inhibitor Bound Dengue NS2B-NS3pro Reveals Multiple Dynamic Binding Modes.
Gibbs AC; Steele R; Liu G; Tounge BA; Montelione GT
Biochemistry; 2018 Mar; 57(10):1591-1602. PubMed ID: 29447443
[TBL] [Abstract][Full Text] [Related]
25. Papaya Leaf Extracts as Potential Dengue Treatment: An In-Silico Study.
Madushanka A; Verma N; Freindorf M; Kraka E
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293162
[TBL] [Abstract][Full Text] [Related]
26. 3D-QSAR pharmacophore-based virtual screening, molecular docking and molecular dynamics simulation toward identifying lead compounds for NS2B-NS3 protease inhibitors.
Luo PH; Zhang XR; Huang L; Yuan L; Zhou XZ; Gao X; Li LS
J Recept Signal Transduct Res; 2017 Oct; 37(5):481-492. PubMed ID: 28758854
[TBL] [Abstract][Full Text] [Related]
27. A Computational Approach Applied to the Study of Potential Allosteric Inhibitors Protease NS2B/NS3 from Dengue Virus.
Costa RAD; Rocha JAPD; Pinheiro AS; Costa ADSSD; Rocha ECMD; Silva RC; Gonçalves ADS; Santos CBR; Brasil DDSB
Molecules; 2022 Jun; 27(13):. PubMed ID: 35807364
[TBL] [Abstract][Full Text] [Related]
28. A pan-serotype dengue virus inhibitor targeting the NS3-NS4B interaction.
Kaptein SJF; Goethals O; Kiemel D; Marchand A; Kesteleyn B; Bonfanti JF; Bardiot D; Stoops B; Jonckers THM; Dallmeier K; Geluykens P; Thys K; Crabbe M; Chatel-Chaix L; Münster M; Querat G; Touret F; de Lamballerie X; Raboisson P; Simmen K; Chaltin P; Bartenschlager R; Van Loock M; Neyts J
Nature; 2021 Oct; 598(7881):504-509. PubMed ID: 34616043
[TBL] [Abstract][Full Text] [Related]
29. Discovery of antiviral molecules for dengue: In silico search and biological evaluation.
Cabarcas-Montalvo M; Maldonado-Rojas W; Montes-Grajales D; Bertel-Sevilla A; Wagner-Döbler I; Sztajer H; Reck M; Flechas-Alarcon M; Ocazionez R; Olivero-Verbel J
Eur J Med Chem; 2016 Mar; 110():87-97. PubMed ID: 26807547
[TBL] [Abstract][Full Text] [Related]
30. Virtual screening of eighteen million compounds against dengue virus: Combined molecular docking and molecular dynamics simulations study.
Mirza SB; Salmas RE; Fatmi MQ; Durdagi S
J Mol Graph Model; 2016 May; 66():99-107. PubMed ID: 27054972
[TBL] [Abstract][Full Text] [Related]
31. The Transactions of NS3 and NS5 in Flaviviral RNA Replication.
Tay MYF; Vasudevan SG
Adv Exp Med Biol; 2018; 1062():147-163. PubMed ID: 29845531
[TBL] [Abstract][Full Text] [Related]
32. Serotype-specific interactions among functional domains of dengue virus 2 nonstructural proteins (NS) 5 and NS3 are crucial for viral RNA replication.
Teramoto T; Balasubramanian A; Choi KH; Padmanabhan R
J Biol Chem; 2017 Jun; 292(23):9465-9479. PubMed ID: 28396347
[TBL] [Abstract][Full Text] [Related]
33. Production of a monoclonal antibody against non-structural protein 3 of dengue-2 virus by intrasplenic injection.
Chen Z; Tian Y; Liu L; An J
Hybridoma (Larchmt); 2008 Dec; 27(6):467-71. PubMed ID: 19108619
[TBL] [Abstract][Full Text] [Related]
34. Small molecule pan-dengue and West Nile virus NS3 protease inhibitors.
Cregar-Hernandez L; Jiao GS; Johnson AT; Lehrer AT; Wong TA; Margosiak SA
Antivir Chem Chemother; 2011 May; 21(5):209-17. PubMed ID: 21566267
[TBL] [Abstract][Full Text] [Related]
35. Allostery in the dengue virus NS3 helicase: Insights into the NTPase cycle from molecular simulations.
Davidson RB; Hendrix J; Geiss BJ; McCullagh M
PLoS Comput Biol; 2018 Apr; 14(4):e1006103. PubMed ID: 29659571
[TBL] [Abstract][Full Text] [Related]
36. A Proline-Rich N-Terminal Region of the Dengue Virus NS3 Is Crucial for Infectious Particle Production.
Gebhard LG; Iglesias NG; Byk LA; Filomatori CV; De Maio FA; Gamarnik AV
J Virol; 2016 Jun; 90(11):5451-61. PubMed ID: 27009958
[TBL] [Abstract][Full Text] [Related]
37. Dual targeting of dengue virus virions and NS1 protein with the heparan sulfate mimic PG545.
Modhiran N; Gandhi NS; Wimmer N; Cheung S; Stacey K; Young PR; Ferro V; Watterson D
Antiviral Res; 2019 Aug; 168():121-127. PubMed ID: 31085206
[TBL] [Abstract][Full Text] [Related]
38. Computer-aided analysis of phytochemicals as potential dengue virus inhibitors based on molecular docking, ADMET and DFT studies.
Qaddir I; Rasool N; Hussain W; Mahmood S
J Vector Borne Dis; 2017; 54(3):255-262. PubMed ID: 29097641
[TBL] [Abstract][Full Text] [Related]
39. Looking for inhibitors of the dengue virus NS5 RNA-dependent RNA-polymerase using a molecular docking approach.
Galiano V; Garcia-Valtanen P; Micol V; Encinar JA
Drug Des Devel Ther; 2016; 10():3163-3181. PubMed ID: 27784988
[TBL] [Abstract][Full Text] [Related]
40. Novel Insights into the Molecular Interaction of a Panduratin A Derivative with the Non Structural Protein (NS3) of Dengue Serotypes: A Molecular Dynamics Study.
Parida P; Yadav RNS; Dehury B; Ghosh D; Mahapatra N; Mitra A; Mohanta TK
Curr Pharm Biotechnol; 2017; 18(9):769-782. PubMed ID: 29173158
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
